56.96% of Global Sepsis Diagnostics Market Revenue is Generated by Immunoassay Segment

 

  Sepsis is a life-threatening disease induced by an overactive immune system in reaction to an infection. As per recent studies, the global prevalence of this life-threatening condition is increasing. World Health Organization (WHO) estimates that this ailment affects over 30 million individuals worldwide and causes over 6 million deaths per year. According to the same source, around 3 million babies and 1.2 million children worldwide are affected by this disease each year. Current sepsis diagnosis approaches rely on non-specific physiological and clinical criteria, making it difficult to distinguish sepsis from a systemic inflammatory response induced by normal inflammation. The preliminary test for infection, coagulation, and reduced oxygen availability is blood testing. 

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-sepsis-diagnostics-market

Data Bridge Market Research analyses that the sepsis diagnostics market is expected to grow at a CAGR of 8.0% in the forecast period of 2022 to 2029 and is expected to reach USD 1,526.76 million by 2029. The increasing level of public-private financing for sepsis diagnostic research activities, the rising incidence of infectious diseases, the high rate of sepsis incidences, and growing government programs to raise sepsis awareness are all likely to drive up demand for sepsis diagnostic devices.

Sepsis Diagnostics Market

Rising prevalence of hospital-acquired infections (HAIs) is expected to drive the market's growth rate during the forecast period.

The most prevalent consequences among hospitalized patients are hospital-acquired infections (HAIs). HAIs, also known as nosocomial infections, are a leading source of morbidity and mortality in hospitals around the world. Urinary tract infections, pneumonia, and sepsis are the most frequent hospital-acquired infections (HAIs). As per the "2020 National and State Healthcare-Associated Infections Progress Report" published by the Centers for Disease Control and Prevention (CDC) in 2021, there was a 24 percent, 35 percent, and 15 percent increase in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia in the United States between 2019 and 2020. As bloodstream infections rise, sepsis diagnostic tools will become more widely used. 

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Techniques (Immunoassay, Molecular Diagnostic, Microbiology and Flow Cytometry), Test Type (Laboratory Testing and Point of Care Testing)

Countries Covered

U.S., Canada, Mexico, U.K., Germany, Italy, France, Spain, Russia, Netherland, Switzerland, Turkey, Belgium, Rest of Europe, China, India, Japan, Australia, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Israel, Egypt, South Africa, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America

Market Players Covered

Trinity Biotech (Ireland), Meridian Bioscience (U.S.), Omega Diagnostics Group PLC. (U.K.), Xcyton Diagnostics Limited (india), Diasorin S.p.A (Italy), Seegene Inc. (South Korea), EKF Diagnostics Holdings plc (U.K.), Axis-Shield Diagnostics Ltd. (U.K.), Immunexpress Inc. (U.S.), Luminex Corporation (U.S.), bioMérieux SA (France), BD (U.S.), Thermo Fisher Scientific Inc.(U.S.), Abbott (U.S), Roche Diagnostics (U.S), Cepheid (U.S.), Beckman Coulter, Inc. (U.S.), T2 Biosystems, Inc. (U.S.), Bruker (U.S.) Ortho Clinical Diagnostics (U.S.)

Data Pointers Covered in Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The sepsis diagnostics market is segmented on the basis of techniques and test type.

  • On the basis of techniques, the global sepsis diagnostics market is segmented into microbiology, molecular diagnostics, immunoassay and flow cytometry. In 2022, immunoassay segment is expected to dominate the global sepsis diagnostics market with 56.96% market share due to the surging prevalence of hospital-acquired infections (HAIs).

In 2022, the immunoassay segment of techniques segment is anticipated to dominate the sepsis diagnostics market

In 2022, the immunoassay segment of this market will dominate the sepsis diagnostics market due to the surging prevalence of hospital-acquired infections (HAIs). The immunoassay segment is expected reach the highest CAGR of 8.1% in the forecast period of 2022-2029.

  • On the basis of test type, the global sepsis diagnostics market is segmented into laboratory testing and point of care testing. In 2022, the laboratory testing segment is expected to dominate the global sepsis diagnostics market with 75.34% market share because lab testing has higher accuracy than POC testing while diagnosing sepsis. The in-depth analysis of the pathogen and its drug resistance profile is offered by clinical laboratory testing.

In 2022, the laboratory testing segment is projected to hold the largest share of test type segment in the sepsis diagnostics market

In 2022, the laboratory testing segment is anticipated to hold the largest share of the global sepsis diagnostics market because lab testing has higher accuracy than POC testing while diagnosing sepsis. Clinical laboratory testing offers an in-depth analysis of the pathogen and its drug resistance profile. The laboratory testing segment is growing with a CAGR of 7.3% in the forecast period of 2022 to 2029.

Major Players

Data Bridge Market Research recognizes the following companies as the major Seegene Inc. (South Korea), Luminex Corporation (U.S.), Cepheid (U.S.), Bruker (U.S.), T2 Biosystems, Inc. (U.S.), Ortho Clinical Diagnostics (U.S.).

Sepsis Diagnostics Market

Market Development

  • In June 2021, bioMérieux announced the acquisition of Specific Diagnostics to distribute a Specific Reveal Rapid AST System in Europe. Rapid AST helps institutions adopt successful Antimicrobial Stewardship (AMS) programmes, which minimizes global AMR burdens. The SPECIFIC REVEAL Rapid AST technology, which is perfectly aligned with bioMérieux's aim of providing novel diagnostics to promote Antimicrobial Stewardship, gives actionable results for Gram-negative bacteria directly from positive blood cultures in an average of 5 hours. This aids clinicians in dealing with the problem of bloodstream infections by allowing for either prompt de-escalation to a more targeted, more suitable, and lower-cost therapy, or life-saving quick escalation to a more effective therapy in the case of a multidrug-resistant (MDR) infection.
  • In January 2020, Inotrem S.A. announced their collaboration with Roche Diagnostics to commercially a mechanism-based companion diagnostic test using a soluble plasma protein (sTREM-1). This collaboration strengthens existing ties between Roche Diagnostics and Inotrem, who have been working together on an in vitro assay for measuring sTREM-1 in septic shock patient plasma samples since 2017. The presence of sTREM-1 in the blood can be used to predict the severity and fate of septic shock patients.
  • In May 2020, Danaher Corporation had announced the launch of the DxH 690T hematology analyzer in the US for the early detection of sepsis. The Early Sepsis Indicator (ESId), which is available on Beckman Coulter's larger high-volume analyzer, the DxH900, is a novel FDA-cleared, hematology-based cellular biomarker included as part of a standard CBC with differential, designed to help emergency department physicians identify adult patients with sepsis or at increased risk of developing sepsis.

Regional Analysis

Geographically, the countries covered in the Sepsis diagnostics market report are U.S., Canada, Mexico, U.K., Germany, Italy, France, Spain, Russia, Netherland, Switzerland, Turkey, Belgium, Rest of Europe, China, India, Japan, Australia, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Israel, Egypt, South Africa, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in Sepsis diagnostics market during the forecast period 2022 - 2029

North America will continue to dominate the Sepsis diagnostics market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to the presence of major key players and well-developed healthcare infrastructure in this region. Also, surging number of the adult population getting diagnosed positive for sepsis will propel the market's growth rate in this region. U.S. dominates the North American region due to the rising adoption rate of advanced technologies for sepsis diagnosis.

Asia-Pacific is estimated to be the fastest growing region in Sepsis diagnostics market the forecast period 2022 - 2029

Asia-Pacific region is anticipated to grow at the highest rate during the forecast period of 2022-2029 due to the growing level healthcare expenditure by the government of developing economies in the region. China dominates the Asia-Pacific region due increasing developments in the healthcare sector and growing government support.

COVID-19 Impact Analysis

The COVID-19 pandemic had a relatively beneficial impact on the sales of sepsis diagnostics. The global spread of COVID-19 and the emergence of sepsis cases among COVID-19 patients were anticipated to augment demand for rapid diagnosis, resulting in a faster adoption of devices, reagents, and test kits for sepsis detection. People postponed health exams as a result of the pandemic, reducing the number of tests performed and reagent sales. The present COVID-19 outbreak has brought attention to the risk that older persons face, as they are more prone to complications such as acute respiratory distress syndrome, which is usually caused by pneumonia and raises the risk of sepsis. As a result, early detection of sepsis in patients with COVID-19 infections is becoming more important.

For more detailed information about the Sepsis diagnostics market report, click here – https://www.databridgemarketresearch.com/reports/global-sepsis-diagnostics-market